Select Language
NT-4
NT-4 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
Tag Free (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
NT4-H5114 |  Human | E. coli | Human NT-4 / Neurotrophin-4 Protein, Tag Free, low endotoxin (MALS verified) |  |  |  |
Total: 1
- 1
NT-4 Background
Neurotrophin-4 (NT-4), also known as NT-5, is a member of the NGF family of neuronal and epithelial growth factors. The neurotrophin family is comprised of at least four proteins including NGF, BDNF, NT-3, and NT-4/5. These secreted cytokines are synthesized as prepropeptides that are proteolytically processed to generate the mature proteins. Their functions including supporting the survival and differentiation of existing neurons, encouraging the growth and differentiation of new neurons and synapses, are required in both the central and the peripheral nervous systems.
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Uliledlimab | TJ-4309; TJ-004309; TJD-5 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis | Details |
| Quemliclustat | AB-680 | Phase 3 Clinical | Arcus Biosciences Inc | Biliary Tract Neoplasms; Pancreatic Neoplasms; Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms, Castration-Resistant; Cholangiocarcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| Oleclumab | MEDI-9447 | Phase 3 Clinical | Medimmune Llc | Prostatic Neoplasms, Castration-Resistant; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Osteosarcoma; Urinary Bladder Neoplasms; Solid tumours; Liposarcoma; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hemangiosarcoma; Ovarian Neoplasms | Details |
| Dalutrafusp alfa | GS-1423; AGEN-1423 | Phase 2 Clinical | Agenus Inc | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| BMS-986179 | BMS-986179 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details |
| Mupadolimab | CPX-006; COR-004 (Corvus Pharmaceuticals); CPI-006 | Phase 2 Clinical | Corvus Pharmaceuticals Inc | Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours | Details |
| Dresbuxelimab | AK-119 | Phase 2 Clinical | Solid tumours; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| S-095024 | S-095024; S095024 | Phase 2 Clinical | Institut De Recherches Internationales Servier, Servier Bio-Innovation LLC, Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| HB-0045 | HB-0045; HB0045 | Phase 2 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd, HuaBo Biopharm Co Ltd | Solid tumours | Details |
| JAB-BX102 | JAB-BX102 | Phase 2 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details |
| PT-199 | PT-199 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| LY-3475070 | LY-3475070 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details |
| Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details | |
| Uprevstobart | INCA-00186 | Phase 1 Clinical | Incyte Corp Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Gastrointestinal Neoplasms | Details |
| AK-137 | AK137; AK-137 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Neoplasms | Details |
| 68GA-DOTA-dPNE | 68GA-DOTA-dPNE | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
| LNF-2008 | LNF-2008; LNF2008 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| HB-0046 | HB0046; HB-0046 | Phase 1 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| HB-0052 | HB-0052; HB0052 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| SYS-6011 | SYS6011; SYS-6011 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours | Details |
| BPI-472372 | BPI-472372 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| BB-1709 | BB-1709 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours | Details |
| PM-1015 | PM1015; PM-1015 | Phase 1 Clinical | Solid tumours | Details | |
| AK-131 | AK-131 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| IBI-325 | IBI-325 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| BR-101 | BR101; BR-101 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
| CB-708 | ATG-037; ATN-037; CB-708; CB708 | Phase 1 Clinical | Calithera Biosciences Inc | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| HLX-23 | HLX-23 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Lymphoma | Details |
| ORIC533 | ORIC-533 | Phase 1 Clinical | Oric Pharmaceuticals Inc | Multiple Myeloma; Neoplasm Metastasis | Details |
| IPH-5301 | IPH-5301 | Phase 1 Clinical | Innate Pharma | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
| HBM-1007 | HBM1007; R 1007; HBM 1007; HBM-1007 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Neoplasms | Details |
| ABSK-051 | ABSK051 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Neoplasms | Details |
- Product List
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland